When comparing pro-BDNF levels during the ALL timepoints, we observed a decrease at diagnosis (1.14 pg/mL) and an increase during the treatment period at induction (3.72 pg/mL), maintenance (7.73 pg/mL), follow-up (7.09 pg/mL), relapse diagnosis (4.77 pg/mL), and relapse treatment (3.86) (Figure 1). Here, BDNF is linked to acute lymphoblastic leukemia.